Development of Neisseria gonorrhoeae in vitro susceptibility test methods for cefixime including quality control guidelines
| Autor: | Ronald N. Jones, Meridith E. Erwin, John A. Washington, Michael A. Pfaller, Frank Koontz, C C Knapp, Patrick R. Murray, E.Hugh Gerlach |
|---|---|
| Rok vydání: | 1991 |
| Předmět: |
Quality Control
Microbiology (medical) food.ingredient medicine.drug_class Cephalosporin Gonorrhea Cefotaxime Microbial Sensitivity Tests Drug resistance medicine.disease_cause Microbiology Agar plate food Drug Stability Cefixime medicine Agar biology business.industry Ceftriaxone Drug Resistance Microbial General Medicine biology.organism_classification medicine.disease Neisseria gonorrhoeae Infectious Diseases Regression Analysis Neisseriaceae business medicine.drug |
| Zdroj: | Diagnostic Microbiology and Infectious Disease. 14:383-388 |
| ISSN: | 0732-8893 |
| DOI: | 10.1016/0732-8893(91)90065-n |
| Popis: | Cefixime was tested in a multilaboratory study to establish susceptibility testing interpretive criteria and quality control (QC) guidelines for Neisseria gonorrhoeae. Interpretive criteria were established by using triplicate testing of 102 representative gonococcal strains. Only a susceptible category was proposed for cefixime (greater than or equal to 31 mm and less than or equal to 0.25 micrograms/ml) because of very rare, resistant isolates. QC ranges [N. gonorrhoeae American Type Culture Collection (ATCC) 49226] were established using multiple GC agar lots, three disk lots, and a number of test replicates consistent with the National Committee for Clinical Laboratory Standards (NCCLS) M23-T guidelines. Cefixime was stable in GC agar medium for at least 21 days when stored at 2 degrees-5 degrees C. Oral third-generation cephalosporins, such as cefixime, appear to represent potentially useful clinical alternatives to parenteral drugs of the same class for single-dose therapy of gonorrhea. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|